Literature DB >> 22017406

Small renal cell carcinoma: oncological outcome with tumour size.

Sascha Pahernik1, Johannes Huber, Jesco Pfitzenmaier, Axel Haferkamp, Markus Hohenfellner.   

Abstract

OBJECTIVE: The aim of the study was to analyse oncological outcomes of patients with renal cell carcinoma (RCC) up to 4 cm in diameter.
MATERIAL AND METHODS: A consecutive series of 396 patients with small RCC was analysed. Tumours were stratified by diameter into three groups: 2 cm (n = 68) for tumours up to 2 cm, 3 cm (n = 172) for tumours between 2.1 and 3.0 cm, and 4 cm (n = 156) for tumours between 3.1 and 4.0 cm in diameter.
RESULTS: Tumour stages were distributed into pT1a in 95.6%, 91.9% and 87.0% and into pT3 in 4.4%, 8.1% and 13.0% for the 2 cm, 3 cm and 4 cm groups, respectively. Metastases at the time of diagnosis were found in 2.9% (n = 2), 7.5% (n = 13) and 9.1% (n = 14) of patients in the 2 cm, 3 cm and 4 cm groups, respectively. The tumour-specific survival was 100%, 96.9% and 94.6% at 1 year, 97.5%, 90.3% and 87.5% at 5 years and 97.5%, 87.3% and 84.1% at 10 years for the 2 cm, 3 cm and 4 cm groups, respectively (p < 0.05).
CONCLUSIONS: Negative prognostic features as well as worse oncological outcome increase with tumour diameter above 2 cm. These data have important implications when considering active surveillance of small renal tumours.

Entities:  

Mesh:

Year:  2011        PMID: 22017406     DOI: 10.3109/00365599.2011.621143

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  2 in total

Review 1.  [Structure of biobanks for urological research].

Authors:  G Hatiboglu; J Huber; E Herpel; I V Popeneciu; J Nyarangi-Dix; D Teber; B A Hadaschik; S Pahernik; S Duensing; M Hohenfellner
Journal:  Urologe A       Date:  2015-09       Impact factor: 0.639

Review 2.  [Active surveillance: concept for renal cell carcinoma?].

Authors:  I Tsaur; D Schilling; A Haferkamp
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.